Introducere. HER2 este implicat în creşterea şi supravieţuirea celulară, iar supraexprimarea sa este determinată în multe tipuri de cancer. În melanomul cutanat datele despre rolul HER2 sunt unice şi contradictorii, supraexpresia prezentând interes în cazurile în care tratamentele convenţionale nu sunt eficiente. Scop şi obiective. Evaluarea expresiei receptorului 2 al factorului de creştere epidermic uman (HER2) în melanomul malign cutanat cu extensie superficială în scopul dezvoltării unui tratament personalizat. Material şi metode. 10 tumori au fost procesate tradiţional (HistoCore PEARL, Histo-Core Arcadia, Leica) şi diagnosticate pe secţiuni HE. Expresia HER2 a fost evaluiată prin tehnici IHC (HER2/ Polyclonal rabbit anti-human c-erbb-2 oncoprotein (Agilent), Mouse/ Rabbit Polydetector Plus DAB HRP (Bio SB)). Hematoxilina Mayer a fost utilizată pentru contracolorare. Rezultate. În calitate de control pozitiv au servit liniile celulare de control (Leica Biosystems) cu scor HER2 pre-determinat. Statusul HER2 a fost interpretat în baza recomandărilor Societăţii Americane a Oncologilor Clinicişti (ASCO, 2014). Cazurile +2 şi +3 au fost considerate HER2+. Tehnici de hibridizare in situ (CISH, FISH) nu au fost utilizate. Cuantificarea a fost realizată la microscopul Zeiss Axiolmager 2.0 cu cameră AxioCam Mrc5 instalată şi ZEN core 3.5 software. Doar într-un singur caz (10%) a fost determinată supraexpresia HER2 (+3). Cazurile apreciate cu 0/+1 (9 cazuri/ 90%) au fost evaluate ca HER2 negative. Concluzii. Amplificarea sau supraexpresia genei HER2 poate duce la creşterea necontrolată a celulelor şi dezvoltarea tumorilor. Melanomul malign cutanat, majoritar nu supraexpresează receptorul HER2. Cazurile unice HER2 pozitive reprezintă o ţintă posibilă în personalizarea tratamentului.
Introduction. HER2 maker is involved in cell growth and survival, and its overexpression is determined in many types of cancer. In cutaneous melanoma, the data on the role of HER2 are unique and contradictory, with overexpression being of interest in cases where conventional treatments are not effective. Objective. Evaluation of human epidermal growth factor receptor 2 (HER2) expression in superficially extending cutaneous malignant melanoma for the purpose of developing personalized treatment. Material and methods. 10 tumors were processed as traditionally (HistoCore PEARL, HistoCore Arcadia, Leica) and diagnosed on HE sections. HER2 expression was assessed by IHC techniques (HER2/ Polyclonal rabbit anti-human c-erbb-2 oncoprotein (Agilent), Mouse/Rabbit Polydetector Plus DAB HRP (Bio SB)). Mayer’s hematoxylin was used for counterstaining. Results. Control cell lines (Leica Biosystems) with a predetermined HER2 score served as positive controls. HER2 status was interpreted based on the recommendations of the American Society of Clinical Oncology (ASCO, 2014). Cases +2 and +3 were considered HER2+. In situ hybridization techniques (CISH, FISH...) were not used. Quantification was performed on a Zeiss AxioImager 2.0 microscope with an AxioCam Mrc5 camera installed and ZEN core 3.5 software. The results were evaluated by two independent pathologists. Only in one case (10%) was HER2 overexpression determined (+3). Cases scored 0/+1 (9 cases/ 90%) were evaluated as HER2 negative. Conclusion. Amplification or overexpression of the HER2 gene can lead to uncontrolled cell growth and tumor development. Our results show that most of cutaneous malignant melanomas do not overexpress the HER2 receptor. Single HER2-positive cases represent a possible target for personalized treatment.
